Baxter International, Inc.
This article was originally published in The Gray Sheet
Executive SummaryDirectors for upcoming cardiovascular device business spin-off in mid-2000 includes Michael Mussallem, who will be CEO and chairman of the new company. He has served as a group VP at Baxter since 1994. Also joining the board are Vernon Loucks, Baxter's current chairman, Avery Dennison Corp. President and CEO Philip Neal, and David Pyott, President and CEO of Allergan, Inc. The new company will have annual sales of approximately $900 mil
You may also be interested in...
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Here's what one researcher in the area, Steven Raman, had to say about the new options.
Novartis’s first digital innovation hub in Asia is launched in India, where the Swiss company hopes to ally with partners to deliver digital solutions for patients at scale.
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.